Håkon Reikvam

Professor

Department of Clinical Science

E-mailHakon.Reikvam@uib.no
Phone+47 55 58 54 08
Visitor Address
Haukeland universitetssykehus, Laboratoriebygget

5009 Bergen
Postal Address
Postboks 7804

5020 Bergen

Publications

Academic article

Show author(s) (2023). Systemic metabolomic profiles in adult patients with bacterial sepsis: Characterization of patient heterogeneity at the time of diagnosis. Biomolecules. 1-21.
Show author(s) (2023). GM-CSF, Flt3-L and IL-4 affect viability and function of conventional dendritic cell types 1 and 2. Frontiers in Immunology. 15 pages.

Show author(s) (2022). Weight gain during treatment course of allogenic hematopoietic stem cell transplantation in patients with hematological malignancies affects treatment outcome. Cytotherapy. 1190-1194.
Show author(s) (2022). Pretransplant Systemic Lipidomic Profiles in Allogeneic Stem Cell Transplant Recipients. Cancers. 21 pages.
Show author(s) (2022). Patients with Bacterial Sepsis Are Heterogeneous with Regard to Their Systemic Lipidomic Profiles. Metabolites. 21 pages.
Show author(s) (2022). Når blodet flyter langsomt. Tidsskrift for Den norske legeforening.
Show author(s) (2022). NPM1-mutated patient-derived AML cells are more vulnerable to rac1 inhibition. Biomedicines. 16 pages.
Show author(s) (2022). Musculoskeletal Chronic Graft versus Host Disease-A Rare Complication to Allogeneic Hematopoietic Stem Cell Transplant: A Case-Based Report and Review of the Literature. Current Oncology. 8415-8430.
Show author(s) (2022). MicroRNA serum profiles and chronic graft-versus-host disease. Blood Advances. 5295-5306.
Show author(s) (2022). Limbic encephalitis following allogeneic hematopoietic stem cell transplantation. Case Reports in Immunology. 1-4.
Show author(s) (2022). Leukemia cutis. Tidsskrift for Den norske legeforening.
Show author(s) (2022). Heterogeneity of patient-derived acute myeloid leukemia cells subjected to SYK in vitro inhibition. International Journal of Molecular Sciences. 21 pages.
Show author(s) (2022). Frequency of JAK2V617F, MPL and CALR driver mutations and associated clinical characteristics in a Norwegian patient cohort with myeloproliferative neoplasms. Scandinavian Journal of Clinical and Laboratory Investigation.
Show author(s) (2022). Endocan in Acute Leukemia: Current Knowledge and Future Perspectives. Biomolecules.
Show author(s) (2022). Eksamensformer i de norske medisinstudiene. Tidsskrift for Den norske legeforening. 1-11.
Show author(s) (2022). Basosquamous Basal Cell Carcinoma with Bone Marrow Metastasis. Current Oncology. 2193-2198.
Show author(s) (2022). An Abrupt Transition to Digital Teaching—Norwegian Medical Students and Their Experiences of Learning Output during the Initial Phase of the COVID-19 Lockdown. Healthcare.

Show author(s) (2021). p53 Protein Isoform Profiles in AML: Correlation with Distinct Differentiation Stages and Response to Epigenetic Differentiation Therapy. Cells. 14 pages.
Show author(s) (2021). Thrombosis and thrombocytopenia after HPV vaccination. Journal of Thrombosis and Haemostasis.
Show author(s) (2021). Spontaneous Splenic Artery Rupture as the First Symptom of Systemic Amyloidosis. Case Reports in Critical Care.
Show author(s) (2021). Proteomic studies of primary acute myeloid leukemia cells derived from patients before and during disease-stabilizing treatment based on all-trans retinoic acid and valproic acid. Cancers.
Show author(s) (2021). Proteomic Characterization of Spontaneous Stress-Induced In Vitro Apoptosis of Human Acute Myeloid Leukemia Cells; Focus on Patient Heterogeneity and Endoplasmic Reticulum Stress. Hemato. 607-627.
Show author(s) (2021). Platelet microparticles protect acute myelogenous leukemia cells against daunorubicin-induced apoptosis. Cancers. 1-17.
Show author(s) (2021). Patient Heterogeneity in Acute Myeloid Leukemia: Leukemic Cell Communication by Release of Soluble Mediators and Its Effects on Mesenchymal Stem Cells. Diseases.
Show author(s) (2021). Kidney failure and abdominal discomfort as initial signs of extramedullary acute myelogenous Leukemia. Clinics and Practice. 459-466.
Show author(s) (2021). Hfe genotype, ferritin levels and transferrin saturation in patients with suspected hereditary hemochromatosis. Genes. 11 pages.
Show author(s) (2021). Effects of the autophagy‐inhibiting agent chloroquine on acute myeloid leukemia cells; characterization of patient heterogeneity. Journal of Personalized Medicine. 1-23.

Show author(s) (2020). Targeting cellular metabolism in acute myeloid leukemia and the role of patient heterogeneity. Cells. 1-26.
Show author(s) (2020). Surgical Treatment of Severe Bowel Obstruction as a Rare Complication Following Allogenic Hematopoietic Stem Cell Transplantation. Transplantology. 102-110.
Show author(s) (2020). Inhibition of NF-κB signaling alters acute myelogenous leukemia cell transcriptomics. Cells. 1-19.
Show author(s) (2020). Hyperferritinemi-katarakt-syndrom. Tidsskrift for Den norske legeforening.
Show author(s) (2020). Hemophagocytic lymphohistiocytosis and miliary tuberculosis in a previously healthy individual: a case report. Journal of Medical Case Reports. 1-9.
Show author(s) (2020). Critical upper airway obstruction as the first symptom of acute myeloid leukemia - An anesthesiologic reminder. Clinics and Practice. 34-36.
Show author(s) (2020). A Patient With Maculopapular Rash and Lichenoid Skin Damage Caused by Ponatinib. Journal of International Medical Research.

Show author(s) (2019). Severe Nephritis as Initial Sign of Waldenström's Macroglobulinemia. Clinics and Practice. 127-132.
Show author(s) (2019). High constitutive cytokine release by primary human acute myeloid leukemia cells is associated with a specific intercellular communication phenotype. Journal of Clinical Medicine.
Show author(s) (2019). En mann i 70-årene med ryggsmerter, mageplager og utslett. Tidsskrift for Den norske legeforening. 7 pages.
Show author(s) (2019). Effects of insulin and pathway inhibitors on the PI3K-Akt-mTOR phosphorylation profile in acute myeloid leukemia cells. Signal Transduction and Targeted Therapy.
Show author(s) (2019). Dasatinib is an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs.
Show author(s) (2019). Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults. Expert Opinion on Investigational Drugs. 411-420.
Show author(s) (2019). Behandling av akutt myelogen leukemi hos eldre. Tidsskrift for Den norske legeforening. 1-6.

Show author(s) (2018). Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic and transcriptomic comparison. Expert opinion on therapeutic targets. 639-653.
Show author(s) (2018). The healthy donor profile of immunoregulatory soluble mediators is altered by stem cell mobilization and apheresis. Cytotherapy. 740-754.
Show author(s) (2018). Successful eradication of leptomeningeal plasma cell disease. Oxford Medical Case Reports. 193-197.
Show author(s) (2018). Resistance to the antiproliferative in vitro effect of PI3K-Akt-mTOR inhibition in primary human acute myeloid leukemia cells is associated with altered cell metabolism. International Journal of Molecular Sciences. 1-18.
Show author(s) (2018). Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis. Biomarker Research.
Show author(s) (2018). Patients with treatment-requiring chronic graft versus host disease after allogeneic stem cell transplantation have altered metabolic profiles due to the disease and immunosuppressive therapy: Potential implication for biomarkers. Frontiers in Immunology. 1-15.
Show author(s) (2018). Inflammatory mediator profiles differ in sepsis patients with and without bacteremia. Frontiers in Immunology. 1-12.
Show author(s) (2018). Cytokine profiling and post-transfusion haemoglobin increment in patients with haematological diseases. Vox Sanguinis. 657-668.
Show author(s) (2018). Clonal heterogeneity reflected by pi3k-akt-mtor signaling in human acute myeloid leukemia cells and its association with adverse prognosis. Cancers. 1-15.
Show author(s) (2018). Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation. Case Reports in Hematology.

Show author(s) (2017). Ringsideroblaster. Tidsskrift for Den norske legeforening.
Show author(s) (2017). Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert opinion on therapeutic targets. 357-369.
Show author(s) (2017). Non-curative surgery for aortoenteric fistula. Journal of Surgical Case Reports (JSCR).
Show author(s) (2017). Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells. BMC Cancer. 1-13.
Show author(s) (2017). CDC25 inhibition in acute myeloid leukemia - A study of patient heterogeneity and the effects of different inhibitors. Molecules. 1-18.
Show author(s) (2017). Altered immune activation and IL-23 signaling in response to Candida albicans in autoimmune polyendocrine syndrome type 1. Frontiers in Immunology. 1-10.
Show author(s) (2017). A prospective observational study on effects of fever on red cell transfusion outcome. Vox Sanguinis. 484-486.

Show author(s) (2016). The pretransplant systemic metabolic profile reflects a risk of acute graft versus host disease after allogeneic stem cell transplantation. Metabolomics.
Show author(s) (2016). Pretransplant levels of CRP and interleukin-6 family cytokines; effects on outcome after allogeneic stem cell transplantation. International Journal of Molecular Sciences.
Show author(s) (2016). Nutrition in allogeneic stem cell transplantion - Clinical guidelines and immunobiological aspects. Current Pharmaceutical Biotechnology. 92-104.
Show author(s) (2016). Myeloproliferative neoplasiar og JAK2-mutasjonar :. Tidsskrift for Den norske legeforening. 1889-1894.
Show author(s) (2016). Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia. Cell Death & Disease. 1-14.
Show author(s) (2016). A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Frontiers in Immunology.

Show author(s) (2015). The importance of sample collection when using single cytokine levels and systemic cytokine profiles as biomarkers - a comparative study of serum versus plasma samples. JIM - Journal of Immunological Methods. 19-28.
Show author(s) (2015). The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Research. 530-541.
Show author(s) (2015). Plasmaceller med inklusjonar. Tidsskrift for Den norske legeforening.
Show author(s) (2015). Metabolic serum profiles for patients receiving allogeneic stem cell transplantation: the pretransplant profile differs for patients with and without posttransplant capillary leak syndrome. Disease Markers. 13 pages.
Show author(s) (2015). Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation. OncoTarget. 2794-2811.
Show author(s) (2015). Effects of cytarabine on activation of human T cells - cytarabine has concentration-dependent effects that are modulated both by valproic acid and all-trans retinoic acid. BMC Pharmacology & Toxicology.
Show author(s) (2015). Connexin expression in human acute myeloid leukemia cells: Identification of patient subsets based on protein and global gene expression profiles. International Journal of Molecular Medicine. 645-652.
Show author(s) (2015). Altered plasma levels of cytokines, soluble adhesion molecules and matrix metalloproteases in venous thrombosis. Thrombosis Research. 30-39.

Show author(s) (2014). Systemic levels of the endothelium-derived soluble adhesion molecules endocan and E-selectin in patients with suspected deep vein thrombosis. SpringerPlus. 1-9.
Show author(s) (2014). Preconditioning serum levels of endothelial cell-derived molecules and the risk of posttransplant complications in patients treated with allogeneic stem cell transplantation. Journal of Transplantation. 1-9.
Show author(s) (2014). Molecular mechanisms of nutlin-3 involve acetylation of p53, histones and heat shock proteins in acute myeloid leukemia. Molecular Cancer.
Show author(s) (2014). Identification of a subset of patients with acute myeloid leukemia characterized by long-term in vitro proliferation and altered cell cycle regulation of the leukemic cells. Expert opinion on therapeutic targets. 1237-1251.
Show author(s) (2014). Comparison of in vitro responses to fresh whole blood and reconstituted whole blood after collagen stimulation. Blood Transfusion. 50-55.
Show author(s) (2014). Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients . Transfusion and Apheresis Science. 97-102.
Show author(s) (2014). Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. British Journal of Haematology. 200-211.

Show author(s) (2013). Targeted anti-leukemic therapy as disease-stabilizing treatment for acute myeloid leukemia relapse after allogeneic stem cell transplantation: will it be possible to combine these strategies with retransplantation or donor lymphocyte infusions? Current Cancer Drug Targets. 30-47.
Show author(s) (2013). Stem cell mobilization and harvesting by leukapheresis alters systemic cytokine levels in patients with multiple myeloma. Cytotherapy. 850-860.
Show author(s) (2013). Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells. OncoTarget. 830-843.
Show author(s) (2013). Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and HSP90 inhibitors. Expert Opinion on Investigational Drugs. 551-563.
Show author(s) (2013). Hyperleukocytosis and leukocytapheresis in acute leukaemias: experience from a single centre and review of the literature of leukocytapheresis in acute myeloid leukaemia. Transfusion Medicine. 397-406.
Show author(s) (2013). Forskningsveiledning - en av de essensielle faktorene på «veien til doktorgrad». UNIPED. 45-54.
Show author(s) (2013). Distinct single cell signal transduction signatures in leukocyte subsets stimulated with khat extract, amphetamine-like cathinone, cathine or norephedrine. BMC Pharmacology & Toxicology. 13 pages.
Show author(s) (2013). Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 554-562.

Show author(s) (2012). The pretransplantation serum cytokine profile in allogeneic stem cell recipients differs from healthy individuals, and various profiles are associated with different risks of posttransplantation complications. Biology of Blood and Marrow Transplantation. 190-199.
Show author(s) (2012). The effects of selective serotonin reuptake inhibitors on platelet function in whole blood and platelet concentrates. Platelets. 299-308.
Show author(s) (2012). Soluble mediators released by acute myeloid leukemia cells increase capillary-like networks. European Journal of Haematology. 478-490.
Show author(s) (2012). Inhibition of Mammalian target of rapamycin in human acute myeloid leukemia cells has diverse effects that depend on the environmental in vitro stress. Bone Marrow Research.
Show author(s) (2012). Expression profile of heat shock proteins in acute myeloid leukaemia patients reveals a distinct signature strongly associated with FLT3 mutation status - consequences and potentials for pharmacological intervention. British Journal of Haematology. 468-480.
Show author(s) (2012). Disease-stabilizing treatment with all-trans retinoic acid and valproic acid in acute myeloid leukemia: Serum hsp70 and hsp90 levels and serum cytokine profiles are determined by the disease, patient age, and anti-leukemic treatment. American Journal of Hematology. 368-376.

Show author(s) (2011). Evaluation of noninvasive methods for the estimation of haemoglobin content in red blood cell concentrates. Transfusion Medicine. 145-149.
Show author(s) (2011). A prospective observational study of the effect of platelet transfusions on levels of platelet-derived cytokines, chemokines and interleukins in acute leukaemia patients with severe chemotherapy-induced cytopenia. European Cytokine Network. 52-62.

Show author(s) (2010). The Mirasol (R) Pathogen Reduction Technology system and quality of platelets stored in platelet additive solution. Blood Transfusion. 186-192.
Show author(s) (2010). Targeting the angiopoietin (Ang)/Tie-2 pathway in the crosstalk between acute myeloid leukaemia and endothelial cells: studies of Tie-2 blocking antibodies, exogenous Ang-2 and inhibition of constitutive agonistic Ang-1 release. Expert Opinion on Investigational Drugs. 169-183.
Show author(s) (2010). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
Show author(s) (2010). A pilot study of the possibility and the feasibility of haemoglobin dosing with red blood cells transfusion. Vox Sanguinis. 71-76.

Show author(s) (2009). Thrombelastography. Transfusion and Apheresis Science. 119-123.
Show author(s) (2009). Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
Show author(s) (2009). Nuclear Factor-kappaB Signaling: A Contributor in Leukemogenesis and a Target for Pharmacological Intervention in Human Acute Myelogenous Leukemia. Critical reviews in oncogenesis. 1-41.

Editorial

Show author(s) (2022). Pure red cell aplasia after hematopoietic stem cell transplantation - experimental therapeutic approaches. Expert Opinion on Investigational Drugs. 881-884.
Show author(s) (2022). Proteomic approaches for untangling pharmacological targets in acute myelogenous leukemia. Expert Review of Proteomics. 73-76.
Show author(s) (2022). Cytomegalovirus induced hemophagocytic lymphohistiocytosis: diagnostic and treatment challenges for the future. Expert Review of Hematology. 667-670.
Show author(s) (2022). Autologous hematopoietic stem cell grafts - moving away from a one-size-fits-all approach. Expert Review of Hematology. 1-4.

Show author(s) (2021). Future perspective: precision medicine to improve treatment results in the settings of allogenic stem cell transplantation for acute myelogenous leukemia. Expert Review of Precision Medicine and Drug Development. 151-155.

Show author(s) (2020). Therapy for acute myelogenous leukemia revisited: moving away from a one-size-fits-all approach. Expert Review of Anticancer Therapy. 1-5.

Show author(s) (2013). Predicting effects of kinase inhibitor in therapy for myeloid malignancies - the challenges in capturing disease heterogeneity. Expert Opinion on Investigational Drugs. 1365-1370.

Show author(s) (2011). Heat shock protein 90 (HSP90) inhibition in acute myeloid leukemia-Targeting of disease heterogeneity through direct and indirect antileukemic effects. Leukemia Research. 1156-1158.

Show author(s) (2010). Therapeutic targeting of NF-kappa B in myelodysplastic syndromes and acute myeloid leukaemia - the biological heterogeneity. Expert opinion on therapeutic targets. 1139-1142.
Show author(s) (2010). Heat shock protein 90 (HSP90) inhibition-From experimental to clinical studies. Leukemia Research. 1422-1423.

Show author(s) (2009). Does the preoperative iron status predict transfusion requirement of orthopedic patients? Transfusion and Apheresis Science. 213-217.

Reader opinion piece

Show author(s) (2012). The surface molecule signature of primary human acute myeloid leukemia (AML) cells is highly associated with NPM1 mutation status. Leukemia. 557-559.

Short communication

Show author(s) (2019). Mondor's disease after extensive training with Nordic walking. Oxford Medical Case Reports. 356-358.